OCT announces exclusive Joint Development Agreement with ex-Google AI experts, Hypatia AI

Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful completion of 'proof of concept' of its AI-enabled drug discovery asset, which it is developing in collaboration with New York-based tech consultancy, Hypatia AI (“Hypatia”). Hypatia is developing a cutting-edge AI tool that will significantly accelerate OCT’s…